PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Probiotic”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 955 records · Page 53Linked to original sources

[Medical applications of probiotics].

Normal microflora of the digestive tract plays an important role in maintaining competence of the immune system. Imbalance of the flora may lead to the development of either diseases related to overgrowth of its selected constituents (post-antibiotic diarrhoea, travellers' diarrhoea or infection by external pathogens--rotavirus diarrhoea) or diseases resulting from altered immunological response (atopy, inflammatory bowel disease, neoplasmas). It is believed that application of probiotics may restore proper composition and functions of the microflora and thus bring new perspectives into prevention and treatment of these illnesses. Prospective studies on mechanisms of the probiotic activities may enable their new medical applications.

Drug Therapy↗

Selection of potentially probiotic Lactobacillus strains towards their inhibitory activity against poultry enteropathogenic bacteria.

Lactobacilli were isolated from chicken gastrointestinal tract and examined for their potentially probiotic properties towards their inhibitory activity against poultry enteropathogenic bacteria. Biochemical tests, ITS-PCR and cell wall protein analysis were used to characterize the Lactobacillus isolates. The identification of isolated Lactobacillus strains based on phenotypic properties was not always satisfactory. ITS-PCR together with protein profile were found to be helpful in strain identification. Lactobacilli were tested for the inhibitory activity against selected strains of poultry enteropathogenic bacteria (Salmonella Enteritidis, Escherichia coli and Clostridium perfringens). Examined supernatants from Lactobacillus broth cultures demonstrated major antimicrobial activity against C. perfringens. Lower antimicrobial activity were observed against E. coli and Salmonella Enteritidis. The strongest inhibition effect were obtained using supernatant of Lactobacillus acidophilus strain 3D. Results received from this study confirmed that identification of Lactobacillus spp. is often tedious. Some isolates, which are in vitro antagonistic against enteropathogenic bacteria may be considered as potential candidates for poultry probiotics, especially in controlling necrotic enteritis caused by C. perfringens.

Animals↗

Effect of probiotic Bifidobacterium longum BB536 [corrected] in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season. A randomized double-blind, placebo-controlled trial.

Probiotic microorganisms have been shown to be effective in the treatment of allergic inflammation and food allergy, but their efficacy remains controversial. This study tested the effect of a yogurt supplemented with a probiotic strain Bifidobacterium longum BB536 in the treatment of Japanese cedar pollinosis (JCPsis). Forty subjects with a clinical history of JCPsis were given yoghurt either containing BB536 (BB536 yoghurt) or without BB536 (placebo yoghurt) at 2 X 100 g per day for 14 weeks, in a randomized, double-blind, placebo-controlled trial. Subjective symptoms and self-care measures were recorded daily and blood samples were taken before and during the intervention (at weeks 4, 9, and 14) to measure the blood parameter levels related to JCPsis. Yoghurt supplemented with BB536 significantly alleviated eye symptoms compared with placebo yoghurt (odds ratio 0.31; 95% confidence interval 0.10-0.97; p = 0.044). Although no statistically significant differences were detected, nasal symptoms such as itching, rhinorrhea, and blockage, as well as throat symptoms tended to be relieved with the BB536 yoghurt. BB536 tended to suppress the decreasing blood levels of interferon-gamma (IFN-y) and the increasing blood eosinophil rates; a significantly higher IFN-gamma level was observed for the difference from baseline at week 4. A decreased trend in the difference from baseline levels of JCP-specific IgE levels was also observed at week 4 in the BB536 group compared with the placebo group. In conclusion, these results suggest that intake of BB536-supplemented yoghurt may relieve JCPsis symptoms, probably through a modulating effect on Th balance.

Adult↗

A probiotic approach to caries management.

The surgical approach has been the predominate mode of caries management for the past 150 years. Dentistry has, however, in recent years moved toward an antibiotic/antimicrobial model of disease management. This approach, however, raises serious questions: (1) do the antibiotic/antimicrobial agents (chlorhexidine, povidone iodine, fluoride, etc) kill all offending organisms?; (2) if so, do the agents preclude the re-entry of the same organisms from external sources?; and (3) if the agents do kill all the offending organisms, do any remaining pathogenic organisms have selective advantage in repopulating the tooth surfaces? To overcome the problems inherent in an antibiotic/antimicrobial approach, probiotic methods are currently under study as means of caries management. This paper discusses probiotic approaches, such as genetically modified Streptococcus mutans and targeted antimicrobials in the management of dental caries. Implications for this approach in the management of other diseases are also presented.

Anti-Bacterial Agents↗

Bioecological and nutritional control of disease: prebiotics, probiotics and synbiotics.

A growing number of patients worlwide suffer acute and chronic diseases. Evidence supports the association of chronic diseases to modern lifestyle habits and malfunction of the immune system. Morbidity and mortality for patients affected of chronic diseases is unacceptably high despite advanced surgical and medical treatments. Nowadays there is an increasing interest in the bioecological and nutritional control of diseases. The use of prebiotics, probiotics and synbiotics, e.g. antioxidants, anti-inflammatory omega-3 lipid emulsions, bioactive fibers, lactic acid bacteria (LAB), etc, appears as a new tool for the treatment of disease. The effects of antioxidants and omega-3 lipid emulsions remain largely unexplored, but significant modulatory effects on neutrophils and morbidity have been observed. It is burning that these compounds are tried in patients including surgically and critically ill patients. Some bioactive fibers and some probiotic bacteria have demonstrated extraordinary efficacy to restore and maintain immunity and prevent complications. Lactic acid bacteria (LAB) have demonstrated ability to reduce or eliminate potential pathogen micro-organisms, as well as various toxins, mutagens and carcinogens; they also promote apoptosis, synthesize and release numerous nutrients, antioxidants, growth-factors, coagulation and other bioactive compounds, and modulate the innate and adaptive immune defence mechanisms. More recent studies suggest that LAB promote and maintain gastrointestinal (GI) motility and prevent GI paralysis and postoperative ileus and have the ability to inhibit inflammation. Further studies are needed to ascertain the molecular mechanisms by which pre-, pro- and synbiotics influence the outcome in a variety of acute and chronic diseases.

Forecasting↗

[A study of the mechanisms of probiotic effect of Bacillus subtilis 8130 strain].

The wild-type Bacillus subtilis strain 8130 secreted metabolites that stimulated two to three times the growth of the test cultures of lactic acid bacteria. It exhibited endoglucanase activity that depended on the composition of nutrient medium. The addition of the product of two-stage culturing of B. subtilis 8130 to the diet of pigs (0.2% of fodder weight) made it possible to increase the daily weight gain by 19% and decrease the consumption of mixed fodder by 10%. Digestion of protein, fat, and other organic compounds increased by 3-4% and cellulose by 12%. It was shown that B. subtilis 8130 is a probiotic with targeted action stimulating digestion (primarily the digestion of cellulose). The enrichment of a dry-beer pellet with the product of solid-phase fermentation by bacillus (1 x 10(8) cells per gram dry pellet) allowed the pellet to entered into the diet of a calf (6% of the weight of fodder with probiotic), causing additional weight gain by 12% and a 10% economy of fodder consumption.

Animal Feed↗

Decreased gum bleeding and reduced gingivitis by the probiotic Lactobacillus reuteri.

The primary aim of this study was to assess if the probiotic Lactobacillus reuteri could be effective in the treatment of gingivitis and further to evaluate the influence of the probiotic on plaque and the lactobacilli population in the saliva. A randomised, placebo-controlled, double blind study was performed over 2 weeks. Fifty-nine patients with moderate to severe gingivitis were included and given one of two different Lactobacillus reuteri formulations (LR-1 or LR-2) at a dose of 2 x 10(8) CFU per day, or a corresponding placebo. At baseline (day 0) gingival index and plaque index were measured on two surfaces and saliva for lactobacilli determination was collected. The patients were instructed how to brush and floss efficiently and study treatment was started.The patients returned on day 14 for final assessment of gingivitis and plaque and saliva was collected. 20 patients were randomised to LR-1, 21 to LR-2 and 18 to placebo. Gingival index fell significantly in all 3 groups (p < 0.0001). LR-1, but not LR-2 improved more than placebo (p < 0.0001). Plaque index fell significantly in LR-1 (p < 0.05) and in LR-2 (p < 0.01) between day o and day 14 but there was no significant change in the placebo group. At day 14, 65% of the patients in LR-1 were colonised with Lactobacillus reuteri and 95% in the LR-2 group. Lactobacillus reuteri was efficacious in reducing both gingivitis and plaque in patients with moderate to severe gingivitis.

Chewing Gum↗

[Probiotics].

While the precise pathophysiology of IBS remains to be elucidated, dysmotility and altered visceral perception/sensation are currently the most popular hypotheses. More recently, roles for enteric infection and intestinal inflammation have been proposed. Probiotics, defined as live or attenuated bacteria or bacterial products that confer a significant health benefit to the host, have the potential to provide a clinical tool to explore these interactions. We reviewed the effects of probiotics on IBS symptoms.

Humans↗

[Probiotics--should we change the treatment strategy for pouchitis?].

Pouchitis is an idiopathic inflammatory bowel disease, which occurs in up to 50% of patients operated on for ulcerative colitis with ileal pouch-anal anastomosis (IPAA). Treatment of pouchitis is still to a large extent empirical, but recently more randomized, double-blind placebo-controlled trials have been conducted. This article reviews the possible treatments for pouchitis, focusing especially on treatment with probiotics, which seem to be a new and promising alternative to antibiotics. We are currently doing clinical trials to determine whether a probiotic is an effective treatment for chronic inflammatory bowel disease.

Anti-Bacterial Agents↗

Protection mechanism of probiotic combination against human pathogens: in vitro adhesion to human intestinal mucus.

In this study we evaluated the ability of commercial strains (L. rhamnosus GG, L. rhamnosus LC705, and P. freudenreichii ssp. shermanii JS) in combination with B. breve 99 or B. lactis Bb12 to inhibit, displace and compete with model pathogens in order to test their influence on the adhesion of selected pathogens to immobilized human intestinal mucus. Our results demonstrate that specific probiotic combinations are able to enhance the inhibition percentages of pathogens adhesion to intestinal mucus when compared to individual strains. This suggests that combinations of probiotic strains are useful and more effective in inhibition of pathogen adhesion than individual strains. Such combinations should be assessed in clinical studies in subjects where the intestinal microbiota aberrancies have been identified.

Antibiosis↗

[Effect of probiotics and yogurt on colonic microflora in subjects with lactose intolerance].

OBJECTIVE: To study the effects of probiotics and yoghurt supplementation on colonic microflora in subjects with lactose intolerance (LI). METHODS: Eleven lactose intolerant volunteers determined by 25g lactose challenge test were recruited and given supplementation with Bifina capsule (with B. longum) and yogurt (with B. animalis, L. bulgaricus, S. thermophilus) for 14 days. The trial was divided into 3 phases: 7-day basal period, 14-day supplementation period and 7-day post-supplementation period. Two lactose challenge tests were performed 1 day before and 1 day after supplementation period respectively, and lactose intolerance symptoms were recorded with questionnaires. Five fecal samples were collected during the trial, and total bacteria and several main groups of bacteria in colon were analyzed by fluorescence in situ hybridization (FISH). The shift of Bifidobacterium species population in colon was analyzed by denaturing gradient gel electrophoresis (DGGE). RESULTS: It was found that LI symptom was alleviated significantly after supplementation (P < 0.05). The amount of total bacteria and the main groups of bacteria (Bifidobacteria, Bacteroides-Prevotella, Eubacteria, Ruminccocc, et al.) was significantly increased during the supplementation period (P < 0.05). The amount of Bifidobacteria during post-supplementation period was significantly higher than that of basal period (P < 0.05), while the amount of other several groups of bacteria decreased. The result of DGGE showed that the extraneous Bifidobacteria species from Bifina capsule and yoghurt could be detected in fecal samples during supplementation period, however there was diversity between volunteers. CONCLUSION: It was suggested that extraneous Bifidobacteria in Bifina capsule and yogurt could resist the effect of gastric acid and bile salt, and survive in colon. Supplementation of probiotics and yogurt could influence the colonic bacteria, and increase the number of main groups of colonic microflora, especially for Bifidobacteria, which could play important role in alleviating LI symptoms.

Adult↗

[Study of probiotic properties of bacteriocinogenic Lactobacillus plantarum G3/3(13) strain].

Bacteriocinogenic culture Lactobacillus plantarum G3/3(13) was tested according to the basic requirements to probiotic strains. The reidentification of the strain was carried out using a set of methods including PCR. It was confirmed that the strain belongs to the species L. plantarum. The studied culture expressed antagonistic activity with respect to Enterococcus faecalis and E. faecium. The susceptibility test to 57 antibiotics of different groups showed that the strain was resistant to oxacillin, cefepyme, lomefloxacin, polymyxin, nalidixic acid and the antifungal antibiotics. High adhesive properties of the microorganism to the human epithelial cells (medium adhesion index was 4.6-5.6; microorganism adhesion index was 4.9-5.9) were shown. Obtained results allow to recommend L. plantarum G3/3(13) for the construction of probiotics.

Anti-Bacterial Agents↗

Effects of probiotics and prebiotics on blood lipids.

Since the early work of Mann and Spoerry, probiotics in the form of fermented milk products have been reputed to have cholesterol-lowering properties in humans. However, studies conducted since the early 1970s have produced equivocal findings, with interpretation of the outcomes complicated by use of excessive quantities of product, inadequate sample sizes, failure to control nutrient intake and energy expenditure and variations in baseline blood lipids. More recent studies are of better quality, but fail to provide convincing evidence that 'live' fermented milk products have cholesterol-lowering efficacy in man. Future studies using probiotics should ensure adequate sample sizes sufficient to detect relatively small changes in blood cholesterol and should be conducted over longer periods of time. The recent introduction of the concept of prebiotics has directed attention towards the possibility that alterations in gut microflora induced by the fermentation of non-digestible components of the diet may also have the potential to influence systemic lipid metabolism. This possibility has been strengthened by the observation that in animals, dietary oligofructosaccharides cause suppression of hepatic triglyceride and VLDL synthesis, resulting in marked reductions in triglyceride, and to a lesser extent cholesterol, levels. Evidence for similar effects in humans is sparse and more studies are needed, particularly with respect to effects on postprandial triglyceride concentrations.

Animals↗

Probiotics: nonantigenic tissue fractions in cancer control.

The effects of probiotics, nonantigenic fractions of normal and malignant cells on tumors, and of similar fractions of normal cells on bacteria and viruses are discussed. The effects are considered in relation to tumor growth and development. In a control group of mice given subcutaneous inoculations only of viable dbrB tumor cells in DBA/1 mice, 100% developed tumors. In a group receiving subcutaneous and intravenous injections of tumor cells and given the tumor fractions, 20% developed lung tumors and 53% developed subcutaneous tumors. In an experiment in which mice received only intravenous injections of viable tumor cells and the tumor fractions, 100% of the controls died with no deaths occurring in the treated group. It is concluded that nonantigenic cellular fractions (probiotics) effective in inducing resistance to some bacterial and viral diseases are effective in inducing resistance to tumors in an inbred strain of mice.

Animals↗

Probiotics in the Treatment of Diarrheal Diseases.

Infections of the gastrointestinal tract are a major health problem worldwide, and many result in death, especially in the Third World. The approach to treatment and prevention of these infections has revolved around antibiotic administration for many years, but the emergence of multidrug-resistant pathogens is forcing people to look at alternatives to antibiotics. For more than 100 years, probiotic remedies (viable organisms that benefit the host by improving the microbial balance) have been used to fight infection. Now, substantial scientific and clinical evidence indicates that certain well-selected probiotic organisms can reduce the risk and duration of diarrhea.

Journal Article↗

Harnessing Probiotic LAB and Bacteriocins for Clean-Label Food Processing and Biopreservation: Omics, Molecular Innovations and Industrial Applications.

The persistence of microbial agents in foods, especially spore forming bacteria is one of the most significant challenges to food preservation and safety, undermining product quality, shelf life, and consumer health. The use of traditional control methods, including thermal processing and chemical preservatives, are increasingly limited by consumer demands for minimally processed foods, and the emergence of resistant microbial strains. Advances have been made in the use of probiotics like lactic acid bacteria (LAB) and their biometabolites like bacteriocins in food processing and preservation, particularly to control biofilm and endospore forming pathogens including Bacillus sp., Listeria sp., Staphylococcus sp., Clostridium sp., E. coli etc. in foods and food processing plants/surfaces. Given the ability of these organisms to cause foodborne illness and form resilient biofilms in the food processing ecosystem and their resistance to the conventional method of their elimination, the antimicrobial peptides (bacteriocins) are gaining increasing prominence as useful alternatives to synthetic antimicrobials in enhancing food safety and combating the threats of these pathogens. This review addresses current information on the inhibition of persistent microbial spoilage contaminants, biofilm-forming pathogens, and spore formers of interest to the food industry using LAB and their bacteriocins. Current developments in isolation, characterization, and mode of action of bacteriocins are explored, including synergistic activity with other preservative hurdle techniques such as encapsulation, and nanobiotechnology. Importantly, there is a focus on the utilization of molecular and omics-based approaches to enable a better understanding of bacteriocin biosynthesis, gene regulation, host-microbe interactions and gut microbiome regulation potential of probiotic LABs, permitting the rational development of targeted and strain-specific interventions. Developments in the incorporation of bacteriocin-producing LAB into functional starter cultures and bio-protective products, and challenges in stability, regulatory approval, and scalability for industrial use, are also discussed in the paper. Despite their considerable potential, broader translation remains constrained by regulatory requirements, production and formulation costs, variable efficacy in complex food matrices, and the limited validation of many candidate bacteriocins beyond laboratory and model-food systems. Collectively, these advances position LAB and their bacteriocins at the leading edge of developing sustainable, clean-label, and efficacious functional foods and food preservation systems. Their functionality can be expanded by integrating genomics, synthetic biology, and predictive modeling for the maximization of their biopreservative potential in diverse food matrices and in gut microbiota modulation.

Bioactive Peptides↗

The possible role of probiotics as dietary antimutagen.

Possible antimutagenic actions of probiotics--mainly lactic acid bacteria--were examined using in vitro and in vivo test systems. In the Ames test with Salmonella typhimurium TA1538 beef extract and nitrosated beef extract were used as mutagens. L. casei showed high antimutagenic activity on mutagenicity induced by nitrosated beef extract only without S9 mix, whereas Omniflora (a lyophilized preparation of lactobacilli and E. coli) and its cell-free culture broth exhibited antimutagenic action only on beef extract. The actions of probiotics were more homogeneous when living animals were used in the tests. Using busulfan as a mutagen both the chromosome aberration test (with Chinese hamster bone marrow cells) and the micronucleus test (with bone marrow cells of Chinese hamsters and mice) showed strong anticlastogenic action when L. casei, Omniflora or yoghurt (with living bifiobacteria) were given orally at the same time as the mutagen. Lactobacilli were effective also after i.p. injection. Cell-free culture broths had no or only weak antimutagenic effects. Mutagen-induced chromosome aberrations and micronuclei were reduced by up to 80% by the lactobacilli.

Animals↗

Antibiotic susceptibility patterns and resistance genes of starter cultures and probiotic bacteria used in food.

A survey of starter and probiotic cultures was carried out to determine the current antibiotic resistance situation in microbial food additives in Switzerland. Two hundred isolates from 90 different sources were typed by molecular and other methods to belong to the genera Lactobacillus (74 samples), Staphylococcus (33 samples), Bifidobacterium (6 samples), Pediococcus (5 samples), or were categorized as lactococci or streptococci (82 samples). They were screened for phenotypic resistances to 20 antibiotics by the disk diffusion method. Twenty-seven isolates exhibiting resistances that are not an intrinsic feature of the respective genera were further analyzed by microarray hybridization as a tool to trace back phenotypic resistances to specific genetic determinants. Their presence was finally verified by PCR amplification or Southern hybridization. These studies resulted in the detection of the tetracycline resistance gene tet(K) in 5 Staphylococcus isolates used as meat starter cultures, the tetracycline resistance gene tet(W) in the probiotic cultures Bifidobacterium lactis DSM 10140 and Lactobacillus reuteri SD 2112 (residing on a plasmid), and the lincosamide resistance gene lnu(A) (formerly linA) in L. reuteri SD 2112.

Animals↗